| Aug 13 |
Humacyte GAAP EPS of -$0.48 misses by $0.24
|
| Aug 13 |
Humacyte Second Quarter 2024 Financial Results and Business Update
|
| Aug 12 |
Humacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 13, 2024
|
| Aug 12 |
Biggest stock movers today: KEY, HUMA, and more
|
| Aug 9 |
Humacyte stock falls 18% on FDA delay for ATEV (update)
|
| Aug 9 |
Humacyte Announces FDA Communication of Additional Time Required to Complete Review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma
|
| Aug 4 |
Companies Like Humacyte (NASDAQ:HUMA) Are In A Position To Invest In Growth
|
| Jul 31 |
Russell 2000 rise: Top 5 best, worst performers during July's rally in small-cap stocks
|
| Jul 31 |
Humacyte Acellular Tissue Engineered Vessel (ATEV™) Meets Primary Endpoints in V007 Phase 3 Clinical Trial in Arteriovenous Access for Hemodialysis
|
| Jul 22 |
Humacyte: Creating New Medical Frontiers With Bioengineered Human Tissue
|
